{"title":"上皮-间质转化(EMT)及其在非小细胞肺癌(NSCLC)获得性表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI)化疗耐药性中的作用","authors":"M. C. P. Dela Cruz, P. M. B. Medina","doi":"10.1016/j.cpt.2024.07.001","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":505523,"journal":{"name":"Cancer Pathogenesis and Therapy","volume":"38 5","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Epithelial-mesenchymal transition (EMT) and its role in acquired epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) chemoresistance in non-small cell lung cancer (NSCLC)\",\"authors\":\"M. C. P. Dela Cruz, P. M. B. Medina\",\"doi\":\"10.1016/j.cpt.2024.07.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":505523,\"journal\":{\"name\":\"Cancer Pathogenesis and Therapy\",\"volume\":\"38 5\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Pathogenesis and Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.cpt.2024.07.001\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Pathogenesis and Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.cpt.2024.07.001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Epithelial-mesenchymal transition (EMT) and its role in acquired epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) chemoresistance in non-small cell lung cancer (NSCLC)